Demographic and baseline clinical characteristics of newly diagnosed adult-type diffuse glioma cases for all 3 cohorts
| Variable . | NMH (n = 258) . | Duke (n = 157) . | UCLA (n = 68) . | Total (n = 483) . |
|---|---|---|---|---|
| Age, y | ||||
| Mean (SD) | 52.8 (16.4) | 56.1 (16.4) | 52 (17.9) | 53.8 (16.7) |
| Median (range) | 55 (18-85) | 59.1 (15.8-88.2) | 56.8 (15.7-87.6) | 57 (15.7-88.2) |
| Missing, n (%) | 0 | 0 | 0 | 0 |
| Sex, n (%) | ||||
| Male | 143 (55.43) | 83 (52.87) | 34 (50) | 260 (53.83) |
| Female | 115 (44.57) | 74 (47.13) | 34 (50) | 223 (46.17) |
| Race, n (%) | ||||
| White | 231 (89.53) | 140 (89.17) | 36 (52.94) | 407 (84.27) |
| Black or African American | 11 (4.26) | 8 (5.1) | 2 (2.94) | 21 (4.35) |
| Asian | 4 (1.55) | 2 (1.27) | 3 (4.41) | 9 (1.86) |
| American Indian or Alaska | 0 | 1 (0.64) | 0 | 1 (0.21) |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 |
| Multiracial | 6 (2.33) | 0 | 0 | 6 (1.24) |
| Other | 0 | 0 | 1 (1.47) | 1 (0.21) |
| Missing | 6 (2.33) | 6 (3.82) | 26 (38.24) | 38 (7.87) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 13 (5.04) | 1 (0.64) | 0 | 14 (2.9) |
| Non-Hispanic or non-Latino | 216 (83.72) | 145 (92.36) | 42 (61.76) | 403 (83.44) |
| Missing | 29 (11.24) | 11 (7.01) | 26 (38.24) | 66 (13.66) |
| Smoker, n (%) | ||||
| Never or former | 228 (88.37) | 145 (92.36) | 57 (83.82) | 430 (89.03) |
| Current | 29 (11.24) | 12 (7.64) | 3 (4.41) | 44 (9.11) |
| Missing | 1 (0.39) | 0 | 8 (11.76) | 9 (1.86) |
| Blood type, n (%) | ||||
| AB | 15 (5.81) | — | — | 15 (3.11) |
| A | 93 (36.05) | — | — | 93 (19.25) |
| B | 31 (12.02) | — | — | 31 (6.42) |
| O | 119 (46.12) | — | — | 119 (24.64) |
| Missing | 0 | 157 (100) | 68 (100) | 225 (46.58) |
| Platelet count (×100 000/μL) | ||||
| Mean (SD) | 24.9 (6.8) | 26.2 (7.6) | 23.3 (6.3) | 24.8 (6.9) |
| Median (range) | 24.2 (7.5-44.8) | 25.1 (13.2-46.6) | 22.6 (13.3-43.8) | 24.2 (7.5-46.6) |
| Missing, n (%) | 12 (4.7) | 102 (65.0) | 10 (14.7) | 124 (25.7) |
| WBC count (×10 000/μL) | ||||
| Mean (SD) | 1.1 (0.5) | 1.1 (0.8) | 1 (0.5) | 1.1 (0.6) |
| Median (range) | 1.1 (0.4-3.7) | 0.9 (0.4-6.1) | 0.9 (0.2-2.3) | 1.1 (0.2-6.1) |
| Missing, n (%) | 12 (4.7) | 102 (65.0) | 10 (14.7) | 124 (25.7) |
| Hemoglobin (g/dL) | ||||
| Mean (SD) | 13.4 (2.3) | 13.8 (1.7) | 13.1 (1.8) | 13.4 (2.1) |
| Median (range) | 13.6 (3-21.4) | 13.4 (10.2-17.1) | 13.2 (8.9-17.2) | 13.5 (3-21.4) |
| Missing, n (%) | 12 (4.7) | 102 (65.0) | 10 (14.7) | 124 (25.7) |
| BMI, kg/m2 | ||||
| Mean (SD) | 27.6 (5.4) | 27.8 (5.3) | 26.6 (5) | 27.5 (5.3) |
| Median (range) | 26.7 (17.7-47.1) | 26.6 (20.2-44) | 25.2 (18.1-42.8) | 26.6 (17.7-47.1) |
| Missing, n (%) | 18 (6.9) | 101 (64.3) | 9 (13.2) | 128 (26.5) |
| Hypertension, n (%) | ||||
| No | 156 (60.47) | 96 (61.15) | 47 (69.12) | 299 (61.9) |
| Yes | 102 (39.53) | 58 (36.94) | 21 (30.88) | 181 (37.47) |
| Missing | 0 | 3 (1.91) | 0 | 3 (0.62) |
| Hyperlipidemia, n (%) | ||||
| No | 187 (72.48) | 124 (78.98) | 42 (61.76) | 353 (73.08) |
| Yes | 71 (27.52) | 33 (21.02) | 21 (30.88) | 125 (25.88) |
| Missing | 0 | 0 | 5 (7.35) | 5 (1.04) |
| Asthma, n (%) | ||||
| No | 241 (93.41) | 155 (98.73) | 57 (83.82) | 453 (93.79) |
| Yes | 17 (6.59) | 2 (1.27) | 4 (5.88) | 23 (4.76) |
| Missing | 0 | 0 | 7 (10.29) | 7 (1.45) |
| Hypothyroidism, n (%) | ||||
| No | 227 (87.98) | 145 (92.36) | 58 (85.29) | 430 (89.03) |
| Yes | 31 (12.02) | 12 (7.64) | 6 (8.82) | 49 (10.14) |
| Missing | 0 | 0 | 4 (5.88) | 4 (0.83) |
| History of VTE, n (%) | ||||
| No | 236 (91.47) | 153 (97.45) | 67 (98.53) | 456 (94.41) |
| Yes | 22 (8.53) | 4 (2.55) | 1 (1.47) | 27 (5.59) |
| Blood coagulation disorder(s), n (%) | ||||
| No | 251 (97.29) | 152 (96.82) | 67 (98.53) | 470 (97.31) |
| Yes | 7 (2.71) | 5 (3.18) | 1 (1.47) | 13 (2.69) |
| IDHmut, n (%) | ||||
| No | 175 (67.83) | 111 (70.7) | 47 (69.12) | 333 (68.94) |
| Yes | 83 (32.17) | 30 (19.11) | 17 (25) | 130 (26.92) |
| Missing | 0 | 16 (10.19) | 4 (5.88) | 20 (4.14) |
| 1p/19q Codeletion, n (%) | ||||
| No | 209 (81.01) | 48 (30.57) | 31 (45.59) | 288 (59.63) |
| Yes | 32 (12.4) | 21 (13.38) | 6 (8.82) | 59 (12.22) |
| Missing | 17 (6.59) | 88 (56.05) | 31 (45.59) | 136 (28.16) |
| MGMT promoter methylation, n (%) | ||||
| No | 113 (43.8) | 89 (56.69) | 27 (39.71) | 229 (47.41) |
| Yes | 139 (53.88) | 36 (22.93) | 26 (38.24) | 201 (41.61) |
| Missing | 6 (2.33) | 32 (20.38) | 15 (22.06) | 53 (10.97) |
| EGFR amplification/mutation, n (%) | ||||
| No | 139 (53.88) | 86 (54.78) | 16 (23.53) | 241 (49.9) |
| Yes | 72 (27.91) | 30 (19.11) | 13 (19.12) | 115 (23.81) |
| Missing | 47 (18.22) | 41 (26.11) | 39 (57.35) | 127 (26.29) |
| Circulating D-dimers (ng/mL) | ||||
| Mean (SD) | 795 (1385.2) | — | — | 795 (1385.2) |
| Median (range) | 380 (63.8-8557.2) | — | — | 380 (63.8-8557.2) |
| Missing, n (%) | 94 (36.4) | 157 (100) | 68 (100) | 319 (66.0) |
| Circulating podoplanin (ng/mL) | ||||
| Mean (SD) | 7.5 (17.4) | — | — | 7.5 (17.4) |
| Median (range) | 0 (0-91.5) | — | — | 0 (0-91.5) |
| Missing, n (%) | 91 (35.3) | 157 (100) | 68 (100) | 316 (65.4) |
| Circulating TF-MV activity (pg/mL) | ||||
| Mean (SD) | 0.6 (0.7) | — | — | 0.6 (0.7) |
| Median (range) | 0.6 (0-3.2) | — | — | 0.6 (0-3.2) |
| Missing, n (%) | 90 (34.9) | 157 (100) | 68 (100) | 315 (65.2) |
| Tumor podoplanin IHC, n (%) | ||||
| 0: Negative | 23 (8.91) | 0 | 0 | 23 (4.76) |
| 1: Weak | 22 (8.53) | 0 | 0 | 22 (4.55) |
| 2: Moderate | 26 (10.08) | 0 | 0 | 26 (5.38) |
| 3: Strong | 42 (16.28) | 0 | 0 | 42 (8.7) |
| 4: Superstrong | 34 (13.18) | 0 | 0 | 34 (7.04) |
| Missing | 111 (43.02) | 157 (100) | 68 (100) | 336 (69.57) |
| Tumor TF IHC, n (%) | ||||
| 0: Negative | 22 (8.53) | 0 | 0 | 22 (4.55) |
| 1: Weak | 27 (10.47) | 0 | 0 | 27 (5.59) |
| 2: Moderate | 26 (10.08) | 0 | 0 | 26 (5.38) |
| 3: Strong | 35 (13.57) | 0 | 0 | 35 (7.25) |
| 4: Superstrong | 23 (8.91) | 0 | 0 | 23 (4.76) |
| Missing | 125 (48.45) | 157 (100) | 68 (100) | 350 (72.46) |
| Radiotherapy, n (%) | ||||
| No | 40 (15.5) | 21 (13.38) | 16 (23.53) | 77 (15.94) |
| Yes | 212 (82.17) | 129 (82.17) | 52 (76.47) | 393 (81.37) |
| Missing | 6 (2.33) | 7 (4.46) | 0 | 13 (2.69) |
| Temozolomide, n (%) | ||||
| No | 36 (13.95) | 17 (10.83) | 16 (23.53) | 69 (14.29) |
| Yes | 216 (83.72) | 133 (84.71) | 52 (76.47) | 401 (83.02) |
| Missing | 6 (2.33) | 7 (4.46) | 0 | 13 (2.69) |
| Bevacizumab, n (%) | ||||
| No | 213 (82.56) | 127 (80.89) | 64 (94.12) | 404 (83.64) |
| Yes | 39 (15.12) | 23 (14.65) | 4 (5.88) | 66 (13.66) |
| Missing | 6 (2.33) | 7 (4.46) | 0 | 13 (2.69) |
| WHO grade, n (%) | ||||
| 2 | 35 (13.57) | 21 (13.38) | 12 (17.65) | 68 (14.08) |
| 3 | 54 (20.93) | 17 (10.83) | 14 (20.59) | 85 (17.6) |
| 4 | 169 (65.5) | 119 (75.8) | 42 (61.76) | 330 (68.32) |
| Histology, n (%) | ||||
| Astrocytoma (includes glioblastoma) | 227 (87.98) | 145 (92.36) | 60 (88.24) | 432 (89.44) |
| Oligodendroglioma | 31 (12.02) | 12 (7.64) | 8 (11.76) | 51 (10.56) |
| Length of hospital stay, d | ||||
| Mean (SD) | 5.4 (4.6) | 2.7 (1.7) | 3.6 (1) | 4.7 (4.2) |
| Median (range) | 4 (1-35) | 2 (1-10) | 3 (2-6) | 3 (1-35) |
| Missing, n (%) | 3 (1.2) | 98 (62.4) | 32 (47.1) | 133 (27.5) |
| Variable . | NMH (n = 258) . | Duke (n = 157) . | UCLA (n = 68) . | Total (n = 483) . |
|---|---|---|---|---|
| Age, y | ||||
| Mean (SD) | 52.8 (16.4) | 56.1 (16.4) | 52 (17.9) | 53.8 (16.7) |
| Median (range) | 55 (18-85) | 59.1 (15.8-88.2) | 56.8 (15.7-87.6) | 57 (15.7-88.2) |
| Missing, n (%) | 0 | 0 | 0 | 0 |
| Sex, n (%) | ||||
| Male | 143 (55.43) | 83 (52.87) | 34 (50) | 260 (53.83) |
| Female | 115 (44.57) | 74 (47.13) | 34 (50) | 223 (46.17) |
| Race, n (%) | ||||
| White | 231 (89.53) | 140 (89.17) | 36 (52.94) | 407 (84.27) |
| Black or African American | 11 (4.26) | 8 (5.1) | 2 (2.94) | 21 (4.35) |
| Asian | 4 (1.55) | 2 (1.27) | 3 (4.41) | 9 (1.86) |
| American Indian or Alaska | 0 | 1 (0.64) | 0 | 1 (0.21) |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 |
| Multiracial | 6 (2.33) | 0 | 0 | 6 (1.24) |
| Other | 0 | 0 | 1 (1.47) | 1 (0.21) |
| Missing | 6 (2.33) | 6 (3.82) | 26 (38.24) | 38 (7.87) |
| Ethnicity, n (%) | ||||
| Hispanic or Latino | 13 (5.04) | 1 (0.64) | 0 | 14 (2.9) |
| Non-Hispanic or non-Latino | 216 (83.72) | 145 (92.36) | 42 (61.76) | 403 (83.44) |
| Missing | 29 (11.24) | 11 (7.01) | 26 (38.24) | 66 (13.66) |
| Smoker, n (%) | ||||
| Never or former | 228 (88.37) | 145 (92.36) | 57 (83.82) | 430 (89.03) |
| Current | 29 (11.24) | 12 (7.64) | 3 (4.41) | 44 (9.11) |
| Missing | 1 (0.39) | 0 | 8 (11.76) | 9 (1.86) |
| Blood type, n (%) | ||||
| AB | 15 (5.81) | — | — | 15 (3.11) |
| A | 93 (36.05) | — | — | 93 (19.25) |
| B | 31 (12.02) | — | — | 31 (6.42) |
| O | 119 (46.12) | — | — | 119 (24.64) |
| Missing | 0 | 157 (100) | 68 (100) | 225 (46.58) |
| Platelet count (×100 000/μL) | ||||
| Mean (SD) | 24.9 (6.8) | 26.2 (7.6) | 23.3 (6.3) | 24.8 (6.9) |
| Median (range) | 24.2 (7.5-44.8) | 25.1 (13.2-46.6) | 22.6 (13.3-43.8) | 24.2 (7.5-46.6) |
| Missing, n (%) | 12 (4.7) | 102 (65.0) | 10 (14.7) | 124 (25.7) |
| WBC count (×10 000/μL) | ||||
| Mean (SD) | 1.1 (0.5) | 1.1 (0.8) | 1 (0.5) | 1.1 (0.6) |
| Median (range) | 1.1 (0.4-3.7) | 0.9 (0.4-6.1) | 0.9 (0.2-2.3) | 1.1 (0.2-6.1) |
| Missing, n (%) | 12 (4.7) | 102 (65.0) | 10 (14.7) | 124 (25.7) |
| Hemoglobin (g/dL) | ||||
| Mean (SD) | 13.4 (2.3) | 13.8 (1.7) | 13.1 (1.8) | 13.4 (2.1) |
| Median (range) | 13.6 (3-21.4) | 13.4 (10.2-17.1) | 13.2 (8.9-17.2) | 13.5 (3-21.4) |
| Missing, n (%) | 12 (4.7) | 102 (65.0) | 10 (14.7) | 124 (25.7) |
| BMI, kg/m2 | ||||
| Mean (SD) | 27.6 (5.4) | 27.8 (5.3) | 26.6 (5) | 27.5 (5.3) |
| Median (range) | 26.7 (17.7-47.1) | 26.6 (20.2-44) | 25.2 (18.1-42.8) | 26.6 (17.7-47.1) |
| Missing, n (%) | 18 (6.9) | 101 (64.3) | 9 (13.2) | 128 (26.5) |
| Hypertension, n (%) | ||||
| No | 156 (60.47) | 96 (61.15) | 47 (69.12) | 299 (61.9) |
| Yes | 102 (39.53) | 58 (36.94) | 21 (30.88) | 181 (37.47) |
| Missing | 0 | 3 (1.91) | 0 | 3 (0.62) |
| Hyperlipidemia, n (%) | ||||
| No | 187 (72.48) | 124 (78.98) | 42 (61.76) | 353 (73.08) |
| Yes | 71 (27.52) | 33 (21.02) | 21 (30.88) | 125 (25.88) |
| Missing | 0 | 0 | 5 (7.35) | 5 (1.04) |
| Asthma, n (%) | ||||
| No | 241 (93.41) | 155 (98.73) | 57 (83.82) | 453 (93.79) |
| Yes | 17 (6.59) | 2 (1.27) | 4 (5.88) | 23 (4.76) |
| Missing | 0 | 0 | 7 (10.29) | 7 (1.45) |
| Hypothyroidism, n (%) | ||||
| No | 227 (87.98) | 145 (92.36) | 58 (85.29) | 430 (89.03) |
| Yes | 31 (12.02) | 12 (7.64) | 6 (8.82) | 49 (10.14) |
| Missing | 0 | 0 | 4 (5.88) | 4 (0.83) |
| History of VTE, n (%) | ||||
| No | 236 (91.47) | 153 (97.45) | 67 (98.53) | 456 (94.41) |
| Yes | 22 (8.53) | 4 (2.55) | 1 (1.47) | 27 (5.59) |
| Blood coagulation disorder(s), n (%) | ||||
| No | 251 (97.29) | 152 (96.82) | 67 (98.53) | 470 (97.31) |
| Yes | 7 (2.71) | 5 (3.18) | 1 (1.47) | 13 (2.69) |
| IDHmut, n (%) | ||||
| No | 175 (67.83) | 111 (70.7) | 47 (69.12) | 333 (68.94) |
| Yes | 83 (32.17) | 30 (19.11) | 17 (25) | 130 (26.92) |
| Missing | 0 | 16 (10.19) | 4 (5.88) | 20 (4.14) |
| 1p/19q Codeletion, n (%) | ||||
| No | 209 (81.01) | 48 (30.57) | 31 (45.59) | 288 (59.63) |
| Yes | 32 (12.4) | 21 (13.38) | 6 (8.82) | 59 (12.22) |
| Missing | 17 (6.59) | 88 (56.05) | 31 (45.59) | 136 (28.16) |
| MGMT promoter methylation, n (%) | ||||
| No | 113 (43.8) | 89 (56.69) | 27 (39.71) | 229 (47.41) |
| Yes | 139 (53.88) | 36 (22.93) | 26 (38.24) | 201 (41.61) |
| Missing | 6 (2.33) | 32 (20.38) | 15 (22.06) | 53 (10.97) |
| EGFR amplification/mutation, n (%) | ||||
| No | 139 (53.88) | 86 (54.78) | 16 (23.53) | 241 (49.9) |
| Yes | 72 (27.91) | 30 (19.11) | 13 (19.12) | 115 (23.81) |
| Missing | 47 (18.22) | 41 (26.11) | 39 (57.35) | 127 (26.29) |
| Circulating D-dimers (ng/mL) | ||||
| Mean (SD) | 795 (1385.2) | — | — | 795 (1385.2) |
| Median (range) | 380 (63.8-8557.2) | — | — | 380 (63.8-8557.2) |
| Missing, n (%) | 94 (36.4) | 157 (100) | 68 (100) | 319 (66.0) |
| Circulating podoplanin (ng/mL) | ||||
| Mean (SD) | 7.5 (17.4) | — | — | 7.5 (17.4) |
| Median (range) | 0 (0-91.5) | — | — | 0 (0-91.5) |
| Missing, n (%) | 91 (35.3) | 157 (100) | 68 (100) | 316 (65.4) |
| Circulating TF-MV activity (pg/mL) | ||||
| Mean (SD) | 0.6 (0.7) | — | — | 0.6 (0.7) |
| Median (range) | 0.6 (0-3.2) | — | — | 0.6 (0-3.2) |
| Missing, n (%) | 90 (34.9) | 157 (100) | 68 (100) | 315 (65.2) |
| Tumor podoplanin IHC, n (%) | ||||
| 0: Negative | 23 (8.91) | 0 | 0 | 23 (4.76) |
| 1: Weak | 22 (8.53) | 0 | 0 | 22 (4.55) |
| 2: Moderate | 26 (10.08) | 0 | 0 | 26 (5.38) |
| 3: Strong | 42 (16.28) | 0 | 0 | 42 (8.7) |
| 4: Superstrong | 34 (13.18) | 0 | 0 | 34 (7.04) |
| Missing | 111 (43.02) | 157 (100) | 68 (100) | 336 (69.57) |
| Tumor TF IHC, n (%) | ||||
| 0: Negative | 22 (8.53) | 0 | 0 | 22 (4.55) |
| 1: Weak | 27 (10.47) | 0 | 0 | 27 (5.59) |
| 2: Moderate | 26 (10.08) | 0 | 0 | 26 (5.38) |
| 3: Strong | 35 (13.57) | 0 | 0 | 35 (7.25) |
| 4: Superstrong | 23 (8.91) | 0 | 0 | 23 (4.76) |
| Missing | 125 (48.45) | 157 (100) | 68 (100) | 350 (72.46) |
| Radiotherapy, n (%) | ||||
| No | 40 (15.5) | 21 (13.38) | 16 (23.53) | 77 (15.94) |
| Yes | 212 (82.17) | 129 (82.17) | 52 (76.47) | 393 (81.37) |
| Missing | 6 (2.33) | 7 (4.46) | 0 | 13 (2.69) |
| Temozolomide, n (%) | ||||
| No | 36 (13.95) | 17 (10.83) | 16 (23.53) | 69 (14.29) |
| Yes | 216 (83.72) | 133 (84.71) | 52 (76.47) | 401 (83.02) |
| Missing | 6 (2.33) | 7 (4.46) | 0 | 13 (2.69) |
| Bevacizumab, n (%) | ||||
| No | 213 (82.56) | 127 (80.89) | 64 (94.12) | 404 (83.64) |
| Yes | 39 (15.12) | 23 (14.65) | 4 (5.88) | 66 (13.66) |
| Missing | 6 (2.33) | 7 (4.46) | 0 | 13 (2.69) |
| WHO grade, n (%) | ||||
| 2 | 35 (13.57) | 21 (13.38) | 12 (17.65) | 68 (14.08) |
| 3 | 54 (20.93) | 17 (10.83) | 14 (20.59) | 85 (17.6) |
| 4 | 169 (65.5) | 119 (75.8) | 42 (61.76) | 330 (68.32) |
| Histology, n (%) | ||||
| Astrocytoma (includes glioblastoma) | 227 (87.98) | 145 (92.36) | 60 (88.24) | 432 (89.44) |
| Oligodendroglioma | 31 (12.02) | 12 (7.64) | 8 (11.76) | 51 (10.56) |
| Length of hospital stay, d | ||||
| Mean (SD) | 5.4 (4.6) | 2.7 (1.7) | 3.6 (1) | 4.7 (4.2) |
| Median (range) | 4 (1-35) | 2 (1-10) | 3 (2-6) | 3 (1-35) |
| Missing, n (%) | 3 (1.2) | 98 (62.4) | 32 (47.1) | 133 (27.5) |
EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; MGMT, O-6-methylguanine–DNA methyltransferase; SD, standard deviation; --, data not available.